Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation.
Xue-Jun GuoXiao-Ting CaiZi-Xuan RongYan-Pei ZhangYu-Xiang WenXue BaiJian WangQiang John FuZe-Qin GuoLi-Li LongSi-Cong MaXin-Ran TangLi LiuJian GuanZhong-Yi DongDe-Hua WuPublished in: BMC medicine (2023)
Compared with ICI monotherapy, ICI combined with RT, rather than with CHEMO or TARGET, is associated with a higher risk of IP in NSCLC patients. Hence, patients receiving these treatments should be carefully monitored for IP.
Keyphrases
- end stage renal disease
- ejection fraction
- small cell lung cancer
- newly diagnosed
- chronic kidney disease
- adverse drug
- combination therapy
- prognostic factors
- peritoneal dialysis
- photodynamic therapy
- electronic health record
- squamous cell carcinoma
- radiation therapy
- patient reported outcomes
- rheumatoid arthritis
- big data
- machine learning
- advanced non small cell lung cancer
- locally advanced
- deep learning
- patient reported